Market Newsdesk

LISHUI, China, Dec. 21, 2020 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced its latest sales win. The Company’s subsidiary, Zhejiang Forest Food Co., Ltd., has received another multi-product order, this time from a Chinese multi-channel customer, with over 100 retail stores in China and Canada, and a major export business. The latest order is for flower mushrooms and donko shiitake.

Flower mushrooms are high-end grade shiitake mushrooms, known for their distinct flower-like cracking pattern on the cap. Donko shiitake is another high-end grade shiitake.

Ms. Yefang Zhang, Farmmi’s Chairwoman and CEO, commented, “Our latest win underscores Farmmi’s continued sales growth momentum and success at partnering with customers capable of building mutually beneficial, long-term relationships. We are really excited to be working with this leading grocery chain and exporter. We share a common vision of enhanced healthy food choices, that are natural and processed less. There has been a fundamental shift occurring in consumer tastes and buying habits with more spending going to natural food choices. We believe this is due to a combination of the inherently better taste with better ingredients, and the perceived benefits of a diet based on healthy, natural foods rather than the heavily processed foods that have grown all too common. In addition, COVID-19 resulted in widespread restaurant closures and a return to self-prepared foods. With people returning to their kitchens demand for high-quality ingredients, which Farmmi is a leading provider of, have remained high, helping to drive our growth and positive outlook.”

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products. The Company’s Farmmi Liangpin Market serves as a trading platform for Chinese geographical indication agricultural products and is a large platform for consumers to access locally sourced agricultural products. For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

View original content:http://www.prnewswire.com/news-releases/farmmi-announces-latest-sales-win-to-multi-channel-customers-with-over-100-retail-stores-in-china-and-canada-301196500.html

SOURCE Farmmi, Inc.

ROCKVILLE, Md., Dec. 21 2020 /PRNewswire/ — CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies, and Retune DSP, a leading provider of Digital Signal Processing Solutions for Voice Control and Communication announced that the Retune VoiceSpot Wake Word Engine is now optimized and available for CEVA’s audio/voice DSPs, including the CEVA-BX, CEVA-X, and CEVA-TeakLite families. CEVA and Retune DSP are already engaged with a lead customer, deploying this collaborative solution in an upcoming smart home device.

VoiceSpot is a high-performance embedded wake word and small vocabulary ASR engine, enabling voice-wake and command and control on memory-constrained, battery-operated edge devices. VoiceSpot achieves high performance levels with very small 30 to 35KB typical model size (depending upon the specific wake-word), with a total memory footprint of under 80KB. CEVA’s audio/voice DSPs are widely deployed in battery-operated edge devices for voice activation and control, including TWS earbuds, smartwatches, action cameras and smart home appliances. These DSPs are ideal for hosting wake word engines like VoiceSpot at extremely low power standby, while also being able to run complex voice front-end algorithms such as echo cancellation and beamforming to improve voice intelligibility and pickup quality.

“CEVA’s wide-reaching success in powering intelligent edge devices with their industry-leading audio/voice DSPs makes them an ideal partner for our VoiceSpot wake word engine,” said Ulrik Kjems, CEO of Retune DSP. “Our small memory footprint solution delivers outstanding voice-wake performance when implemented on the CEVA DSPs. Together, we can accelerate the adoption of voice command and control in smart devices, no matter the form factor or power constraints.”

“Retune DSP is a valued algorithm partner to CEVA, and we’re pleased to announce our collaboration with them around their VoiceSpot technology,” said Moshe Sheier, Vice President of Marketing at CEVA. “Voice is gaining rapid momentum as a must-have user interface for many smart devices and VoiceSpot running on our audio/voice DSPs provides a compelling offering for this burgeoning market.”

CEVA’s scalable audio and sensor hub DSPs are optimized for sound processing applications ranging from always-on voice control up to multiple sensors fusion. They have been specifically designed to tackle multi-microphone speech processing use-cases, high quality audio playback and post-processing, and on-device sound neural network implementations. In addition, a large 3rd party ecosystem of audio/voice software, hardware and development tools companies have optimized their solutions for CEVA DSPs, for a wide array of use cases and applications. For more information on CEVA’s audio and voice product offerings, visit https://www.ceva-dsp.com/app/audio-voice-and-speech/.

About Retune DSP
Founded in 2012, Retune DSP, is a world-wide leader in DSP Software Solutions for Voice Control and Voice Communications.  Headquartered at DTU Science Park in greater Copenhagen, Denmark, Retune DSP maintains offices in the USA and China. For more information, visit https://www.retune-dsp.com/.

About CEVA, Inc.
CEVA is the leading licensor of wireless connectivity and smart sensing technologies. We offer Digital Signal Processors, AI processors, wireless platforms and complementary software for sensor fusion, image enhancement, computer vision, voice input and artificial intelligence, all of which are key enabling technologies for a smarter, connected world. We partner with semiconductor companies and OEMs worldwide to create power-efficient, intelligent and connected devices for a range of end markets, including mobile, consumer, automotive, robotics, industrial and IoT. Our ultra-low-power IPs include comprehensive DSP-based platforms for 5G baseband processing in mobile and infrastructure, advanced imaging and computer vision for any camera-enabled device and audio/voice/speech and ultra-low power always-on/sensing applications for multiple IoT markets. For sensor fusion, our Hillcrest Labs sensor processing technologies provide a broad range of sensor fusion software and IMU solutions for AR/VR, robotics, remote controls, and IoT. For artificial intelligence, we offer a family of AI processors capable of handling the complete gamut of neural network workloads, on-device. For wireless IoT, we offer the industry’s most widely adopted IPs for Bluetooth (low energy and dual mode), Wi-Fi 4/5/6 (802.11n/ac/ax) and NB-IoT. Visit us at www.ceva-dsp.com and follow us on Twitter, YouTube,Facebook, LinkedIn and Instagram.

Logo – https://mma.prnewswire.com/media/74483/ceva__inc__logo.jpg

View original content:http://www.prnewswire.com/news-releases/retune-dsps-wake-word-engine-now-available-for-ceva-audiovoice-dsps-301196444.html

SOURCE CEVA, Inc.

WOONSOCKET, R.I., Dec. 21, 2020 /PRNewswire/ — CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the early results of the previously announced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) and that it is amending the Tender Offers by increasing the Aggregate Maximum Amount (as defined below) of the Tender Offers to $4,500,000,000 from $4,000,000,000 and by increasing the 2025 Notes Maximum Amount (as defined below) to $1,049,919,000 from $1,000,000,000 and the 2028 Notes Maximum Amount (as defined below) to $1,950,081,000 from $1,500,000,000. The Tender Offers, as amended, consist of (i) up to $1,500,000,000 aggregate principal amount (the “2023 Notes Maximum Amount”) of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023 issued by its wholly-owned subsidiary, Aetna Inc. (collectively, the “2023 Notes”) in the priorities set forth in the table below (the “2023 Notes Tender Offers”), (ii) up to $1,049,919,000 aggregate principal amount (as increased and amended, the “2025 Notes Maximum Amount”) of its 4.100% Senior Notes due 2025 and 3.875% Senior Notes due 2025 (collectively, the “2025 Notes”) in the priorities set forth in the table below (the “2025 Notes Tender Offers”) and (iii) up to $1,950,081,000 principal amount (as increased and amended, the “2028 Notes Maximum Amount” and, together with the 2023 Notes Maximum Amount and the 2025 Notes Maximum Amount, the “Maximum Amounts”) of its 4.300% Senior Notes due 2028 (the “2028 Notes”, and, together with the 2023 Notes and the 2025 Notes, the “Notes”). Each group of Tender Offers that constitutes the 2023 Notes Tender Offers, the 2025 Notes Tender Offers or the 2028 Notes Tender Offer are referred to as the “Capped Tender Offers”. The sum of the increased 2023 Notes Maximum Amount, the 2025 Notes Maximum Amount and the 2028 Notes Maximum Amount is $4,500,000,000 (as increased and amended, the “Aggregate Maximum Amount”), which represents the aggregate principal amount of the Notes subject to the Tender Offers and excludes any Accrued Interest (as defined below) or Early Tender Payment (as defined below). The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 7, 2020 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Tender Offers. The Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes.

The consideration to be paid in the Tender Offers for each series of Notes validly tendered and expected to be accepted for purchase as described in the Offer to Purchase (the “Total Consideration”) will be determined at 9:00 a.m., New York City time, on December 21, 2020.

As of 5:00 p.m., New York City time, on December 18, 2020 (the “Early Tender Date”), as reported by D.F. King & Co., Inc., the Tender and Information Agent for the Tender Offers, the principal amounts of the Notes listed in the table above have been validly tendered and not validly withdrawn. The Withdrawal Deadline of 5:00 p.m., New York City time, on December 18, 2020 has passed and, accordingly, Notes validly tendered in the Tender Offers may no longer be withdrawn.

CVS Health expects to accept for purchase and make payment for Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date on December 22, 2020 (the “Early Settlement Date”), subject to the acceptance priority levels applicable to the relevant series as described in the Offer to Purchase and, in the case of the 3.700% Senior Notes due 2023 for the 2023 Notes Tender Offers and in the case of the 4.300% Senior Notes due 2028 for the 2028 Notes Tender Offer to proration as described below.

Because the aggregate principal amount of 2023 Notes validly tendered would exceed the 2023 Notes Maximum Amount, CVS Health expects that it will accept validly tendered 3.700% Senior Notes due 2023 on a prorated basis in accordance with the Offer to Purchase and none of the validly tendered 2.800% Senior Notes due 2023. Because the aggregate principal amount of 2025 Notes validly tendered would exceed the 2025 Notes Maximum Amount, CVS Health expects that it will accept all of the validly tendered 4.100% Senior Notes due 2025 and none of the 3.875% Senior Notes due 2025. Because the principal amount of 2028 Notes validly tendered would exceed the 2028 Notes Maximum Amount, CVS Health expects that it will accept validly tendered 4.300% Senior Notes due 2028 on a prorated basis in accordance with the Offer to Purchase.

Because CVS Health expects to accept for purchase the Maximum Aggregate Amount of Notes, no additional Notes will be purchased pursuant to the Tender Offers after the Early Settlement Date. In connection with the recent announcement by the U.S. government that executive departments and agencies of the federal government will be closed on December 24, 2020, the expiration date (the “Expiration Date”) will be changed from 11:59 p.m., New York City time, January 5, 2021 to 11:59 p.m., New York City time, January 6, 2021. As described in the Offer to Purchase, Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account.

Holders of all Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase are eligible to receive the applicable Total Consideration, which includes the applicable Early Tender Payment of $30 per $1,000 principal amount of Notes tendered at or prior to the Early Tender Date (the “Early Tender Payment”). In addition to the applicable Total Consideration, Holders of Notes accepted for purchase will receive accrued and unpaid interest up to, but not including, the Early Settlement Date (“Accrued Interest”).

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Tender Offers at any time prior to the Expiration Date. The Tender Offers are not conditioned on any minimum principal amount of Notes being tendered but the Tender Offers are subject to certain conditions as described in the Offer to Purchase. Each Tender Offer is a separate offer. None of the Capped Tender Offers are conditioned on each other. Each Tender Offer may be individually amended, extended or terminated by CVS Health.

CVS Health has retained Barclays Capital Inc., BofA Securities, Inc. and Goldman Sachs & Co. LLC to act as Dealer Managers for the Tender Offers. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offers.  Requests for assistance relating to the procedures for tendering Notes may be directed to the Tender and Information Agent either by email at [email protected], or by phone (212) 269-5550 (for banks and brokers only) or (800) 714-3305 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offers may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect), BofA Securities, Inc. at (980) 387-3907 (collect) or Goldman Sachs & Co. LLC at (212) 902-6351 (collect). Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offers. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offers, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is a different kind of health care company. We are a diversified health services company with nearly 300,000 employees united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. Built on a foundation of unmatched community presence, our diversified model engages one in three Americans each year. From our innovative new services at HealthHUB^® locations, to transformative programs that help manage chronic conditions, we are making health care more accessible, more affordable… and simply better. Learn more about how we’re transforming health at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties related to the COVID-19 pandemic, the geographies impacted and the severity and duration of the pandemic, the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns, and the timing, scope and impact of stimulus legislation and other federal, state and local governmental responses to the pandemic, as well as the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 and our recently filed Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cvs-health-corporation-announces-early-results-and-upsize-of-previously-announced-cash-tender-offers-to-an-aggregate-principal-amount-of-4-500-000-000-from-4-000-000-000-of-certain-outstanding-notes-301196443.html

SOURCE CVS Health Corporation

MINNEAPOLIS, Dec. 21, 2020 /PRNewswire/ — Target Corporation (NYSE: TGT) is making last-minute holiday shopping fast, safe and easy in the final days before Christmas, inviting guests to use its contactless same-day pickup and delivery options up until 5 p.m. on Christmas Eve – no membership required.

• Order Pickup and Drive Up: Guests can place their orders at the click of a button up to 5 p.m. on Dec. 24 to ensure free pickup up to the very last minute.
• Same-Day Delivery with Shipt: Orders can be delivered to guests’ doorsteps by professional shoppers as late as5 p.m. on Dec. 24. Delivery times vary by location and shopper availability.

“Target teams across the country are ready to help guests get their last-minute items safely and easily,” says Mark Schindele, Target’s chief stores officer. “All season long, our nearly 1,900 stores have been delivering holiday joy to our guests no matter how they want to shop, and we’ve dedicated even more team members to our same-day services to make sure guests can get their online orders in plenty of time to celebrate.”

For guests looking to check a few final gifts off their holiday shopping lists, Target has taken steps to make its same-day services even safer and easier for last-minute shopping with:

• Thousands more gifts and essentials available via its popular same-day services this holiday. Target’s free, contactless Order Pickup and Drive Up services offer a broad assortment across the store, ranging from gifts and décor to place settings and fresh groceries – ready within hours. Same-Day Delivery with Shipt also offers thousands of products, including the most popular gifts of 2020, groceries, apparel, cleaning supplies and essentials for the whole family.
• Double the Drive Up parking spaces from last year. Drive Up, Target’s highest-rated service, allows guests to shop for thousands of items via the Target app and have them brought directly to their cars within minutes of arriving at the store. New this holiday season, Target doubled the total number of Drive Up spots – adding nearly 8,000 more – making it easier and faster for guests to pick up their orders.
• Even more helpful team members dedicated to safe and speedy service. This holiday, twice as many store team members will be focused on delivering same-day service than last year. Shipt also added 150,000 shoppers this season so even more same-day delivery windows are available for guests with last-minute gift lists.
• No membership required. Guests can enjoy these same-day fulfillment options to score all the items they need, up until the very last minute (5 p.m. on Dec. 24), without needing a membership.

For more information about Target’s same-day fulfillment services and how the retailer is making the holiday shopping season reliable, safe and more convenient than ever, visit Target.com.

About Target Corporation

Minneapolis-based Target Corporation (NYSE: TGT) serves guests at nearly 1,900 stores and at Target.com. Since 1946, Target has given 5 percent of its profit to communities, which today equals millions of dollars a week. For the latest store count or for more information, visit Target.com/Pressroom. For a behind-the-scenes look at Target, visit Target.com/abullseyeview or follow @TargetNews on Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/target-announces-contactless-pick-up-and-at-home-delivery-services-through-5-pm-dec-24-301196439.html

SOURCE Target Corporation

PLANO, Texas, Dec. 21, 2020 /PRNewswire/ — Toyota’s second wave of custom SEMA vehicles break cover today, just in time for the holidays. The 2021 GR Supra Sport Top and overlanding-ready TRD-Sport Trailer ensure that Toyota’s on- and off-road performance and adventure concepts continue to inspire Toyota fans and the automotive aftermarket.                                                         

This year Toyota’s two-wave release plans mean that SEMA lives on long after the show. The company previously unveiled four builds in its wave one SEMA360 Showcase presentation, held Nov. 2, 2020. SEMA360 is the Specialty Equipment Market Association’s (SEMA) online program connecting the automotive aftermarket industry in a year that makes the traditional SEMA Show impossible.

“Our wave one reveals whet Toyota fans’ appetite with four creations – a bold, hand-painted GR Supra, two GR Supra drift cars, and an outrageous overlanding-ready Tacoma pickup,” said Ed Laukes, group vice president – Toyota Division Marketing. “But we saved the best for last, and today we’re proud to show off our latest creations, the 2021 GR Supra Sport Top and the TRD-Sport Trailer, among some additional content as well.”

The new 2021 GR Supra Sport Top concept is a perfect follow up to the wildly popular 2020 GR Supra Heritage Edition that debuted at Toyota’s 2019 SEMA Show display, exciting Supra fans worldwide with its custom visual and performance upgrades paying homage to the iconic MKIV Supra from the late ’90s. And Toyota’s TRD-Sport Trailer answers the backroads adventure calling and the growing popularity of overlanding getaways in a year where socializing with family and friends is a challenge.

Highlights from Toyota’s second wave of SEMA360 Showcase creations include:

2021 GR Supra Sport Top
Inspired by the overwhelming response to the GR Supra Heritage Edition that debuted last year, Toyota set out to dream up a fitting companion. Conceptualizing an open-air tribute to removable-top Supra models of the past, the team put much thought into the unprecedented task of removing the roof and a significant part of the GR Supra’s structure. The crew ensured structural rigidity by reinforcing large sections of the vehicle’s frame. The now iconic removeable roof includes two composite panels that can be stored in the car’s trunk. Unlike a “T-Top” car, there is no center bar down the middle, just open air as far as the eye can see. As a sibling to the GR Supra Heritage Edition, the Sport Top delivers similar styling cues like the MKIV-inspired basket handle wing and round taillights.  At the same time, it has a striking profile all its own that includes a sexy black piano-finish canopy over the top.

TRD-Sport Trailer
Overlanding’s growing popularity inspired the Toyota team to think outside the box, as they sought to make a true overland trailer out of a Tacoma pickup bed. The truly over-the-top TRD-Sport Trailer concept serves as a base camp to extend adventurers’ off-highway fun while being pulled by a Toyota truck or SUV. It features a remote-operated scissor-lift that raises an innovative platform several feet out of the bed. There’s a Yakima four-person tent with an awning and fly fishing-pole holders, a custom-built toilet and trash can, a refrigerator, a hot water heater, fresh and gray water holding tanks, a slide-out sink and stove, and efficient campsite lighting. And that’s just getting started, as the details and campsite features are nearly endless.

2020 GR Supra Heritage Edition
This 500-plus horsepower sports car wowed Toyota Supra fans when it debuted late last year, and it makes an encore appearance in 2020 as the ‘take it to the next level’ inspiration for this year’s GR Supra Sport Top. Returning to the spotlight for Toyota’s second wave of content, this one-off creation painted in Re-entry Red continues to excite fans with its retro-inspired custom headlights, taillights, and MKIV-style rear wing. Upgrades such as bigger brakes, tuned engine, turbocharger and ECU, and custom front and rear suspension ensure it performs as spectacularly as it looks.

The Ornamental Conifer Supra and the 4WD Overland-Ready Tacoma also get a reprise from last month with a freshening of new materials.

The final episodes for the GR Supra Sport Top and TRD-Sport Trailer can be found here:

• GR Supra Sport Top Episode 3
• TRD-Sport Trailer Episode 3

About Toyota


Toyota (NYSE:TM) has been a part of the cultural fabric in the U.S. for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships.

Toyota has created a tremendous value chain and directly employs more than 36,000 in the U.S. The company has contributed world-class design, engineering, and assembly of more than 30 million cars and trucks at our 9 manufacturing plants, 10 including our joint venture in Alabama that is scheduled to begin production in 2021.

To help inspire the next generation for a career in STEM-based fields, including mobility, Toyota launched its virtual education hub at

www.TourToyota.com

 with an immersive experience and chance to visit many of our U.S. manufacturing facilities. The hub also includes a series of free STEM-based lessons and curriculum through Toyota USA Foundation partners, virtual field trips and more. For more information about Toyota, visit

www.toyotanewsroom.com

.

Media Contacts:

Zachary Reed

[email protected] 
469-292-3499

Joshua Burns

[email protected] 
469-292-6449

For customer inquiries, please call: 800-331-4331
Note to Editors: Photos and b-roll can be found on ToyotaNewsroom.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/toyota-reveals-additional-sema-builds-based-on-supra-and-tacoma-301196353.html

SOURCE Toyota

WOONSOCKET, R.I., Dec. 21, 2020 /PRNewswire/ — CVS Health (NYSE: CVS) has formally launched its COVID-19 vaccination program for long-term care facilities, whose residents have been disproportionality impacted by the pandemic. CVS Pharmacy teams will administer the first dose of the Pfizer vaccine in facilities across 12 states this week, and the company expects to vaccinate up to four million residents and staff at over 40,000 long-term care facilities through the program.

“Today’s rollout is the culmination of months of internal planning and demonstrates how the private sector can use its expertise to help solve some of our most critical challenges,” said Larry J. Merlo, President and Chief Executive Officer, CVS Health. “I’m grateful for the herculean efforts of everyone involved, including our health care professionals who will be deployed throughout the country to bring peace of mind to long-term care facility residents, staff, and their loved ones.”

CVS Pharmacy teams will make three visits to each long-term care facility to ensure residents and staff receive their initial shot and critical booster. The majority of residents and staff will be fully vaccinated three to four weeks after the first visit, depending on which vaccine they receive. CVS Health expects to complete its long-term care facility vaccination effort in approximately 12 weeks.

CVS Health will administer COVID-19 vaccinations starting this week in the following states: Connecticut, Florida, Kentucky, Maine, Maryland, Nevada, New Hampshire, New York, Ohio, Oklahoma, Oregon, and Vermont. Vaccinations will begin in 36 more states, as well as the District of Columbia, on December 28. Puerto Rico will activate on January 4.

The long-term care facility vaccination effort is a precursor to the eventual availability of COVID-19 vaccines at all CVS Pharmacy locations throughout the country subject to product availability and prioritization of populations, which will be determined by states. Vaccines in a retail setting will be offered on an appointment-only basis via CVS.com or through the CVS Pharmacy app, and there will be a dedicated 800 number for people without online access. CVS Pharmacy will have the capacity to administer 20 – 25 million shots per month.

“Vaccinating one of our most vulnerable populations is the latest milestone in our multifaceted pandemic response, which includes testing more than 10 million people for the virus since March,” stated Karen S. Lynch, currently Executive Vice President, CVS Health and President, Aetna, who will become the company’s next President and CEO on February 1. “The eventual availability of COVID-19 vaccines in communities across the country will bring us one step closer to overcoming the most significant health challenge of our lifetime.”

Multimedia assets from a December 18 visit to a long-term care facility in Connecticut are available here, in addition to interviews with CVS Health executives. More information on steps CVS Health has taken to address the pandemic is available at the company’s frequently updated COVID-19 resource center.

About CVS Health
CVS Health is a different kind of health care company. We are a diversified health services company with nearly 300,000 employees united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. Built on a foundation of unmatched community presence, our diversified model engages one in three Americans each year. From our innovative new services at HealthHUB® locations, to transformative programs that help manage chronic conditions, we are making health care more accessible, more affordable and simply better. Learn more about how we’re transforming health at www.cvshealth.com.

Media contact
T.J. Crawford
212-457-0583
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/cvs-health-begins-administering-covid-19-vaccines-in-long-term-care-facilities-301196490.html

SOURCE CVS Health

CENTREVILLE, Va., Dec. 21, 2020 /PRNewswire/ — Parsons Corporation (NYSE: PSN) announced today that Carey Smith, president and chief operating officer at Parsons, has been appointed to the company’s board of directors.

Smith is responsible for Parsons’ global operations and implementing the corporate growth strategy built on continuous technology innovation.

“Carey has been central to our growth and success since joining Parsons,” said Chuck Harrington, chairman and chief executive officer of Parsons Corporation. “Her proven track record at Parsons, operational leadership, proximity to our customers and their needs, and experience on other boards make her a natural addition to our board. On behalf of my fellow directors, I am pleased to welcome Carey to the board and look forward to her immediate contributions.”

“It’s been an honor working with my Parsons colleagues to deliver a better world and I am eager to be a member of the board to drive continued innovation and growth,” said Carey Smith, president and chief operating officer. “We will continue solving our customers’ most difficult challenges with differentiated products and solutions.”

Smith joined Parsons in 2016 as president of the firm’s Federal Solutions business where she helped shape and grow the current portfolio. She was appointed COO in 2018 when the company merged its Federal Solutions and Critical Infrastructure business segments to better position for technologically converged defense, intelligence and critical infrastructure markets and provide greater value for our customers. In 2019, she was promoted to president and COO.

Smith received an honorary doctorate degree from Ohio Northern University, a master’s degree in electrical engineering from Syracuse University and a bachelor’s degree in electrical engineering from Ohio Northern University. She serves on the boards of Edison International, the U.S. Geospatial Intelligence Foundation and the Professional Services Council and has received numerous industry awards.

To learn more about the Parsons’ board, please visit: https://www.parsons.com/about/leadership/

About Parsons Corporation

Parsons (NYSE: PSN) is a leading disruptive technology provider in the global defense, intelligence, and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, connected infrastructure, and smart cities. Please visit parsons.com and follow us on LinkedIn and Facebook to learn how we’re making an impact.

Media Contact:
Bryce McDevitt           
+1 703.851.4425
[email protected]

Investor Relations Contact:
 Dave Spille
 + 1 571.655.8264
 [email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/parsons-corporation-appoints-carey-smith-to-board-of-directors-301196480.html

SOURCE Parsons Corporation

MINNEAPOLIS, Dec. 21, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301196420.html

SOURCE Bio-Techne Corporation